Inovio Pharmaceuticals, Inc.

INO Details
 
Received Order from World Health Organization: Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a biotechnology company focused on designing DNA medicines to treat/cure diseases associated with HPV, cancer, and infectious diseases. Recently, the company informed that it has received an accelerated timeline for developing its DNA vaccine INO-4800 to address COVID-19. The company further informed that with its modern DNA medicines platform, the company designed its DNA vaccine INO-4800 in three hours after the publication of the genetic sequence of the novel coronavirus that causes COVID-19.

Q3FY19 Operational Highlights for the Period ended 30 September 2019: INO declared its quarterly results, wherein the company reported total revenue of $866,863, down from $2,000,868 on the previous corresponding period, due to a reduction in manufacturing services under the AstraZeneca collaboration. Research and development expenses for the quarter stood at $19.1 million, down from $21.9 million, due to reductions in both employee compensation expense and drug manufacturing expense. General and administrative expenses declined to $5.7 million from $6.8 million in Q3FY18, on account of decreases in employee compensation, depreciation expense and legal expenses. However, the decline was partially offset by personnel-related restructuring charge related to one-time employee termination costs incurred during the quarter. The company reported a net loss of $23,536,452, indicating an improvement from $25,015,672 in the previous corresponding period.


Q3FY19 Income Statement Highlights (Source: Company Reports)

Balance Sheet Update: As on 30^th September 2019, the company reported total current assets of $98,812,541, which includes cash and cash equivalents of $15,853,236 and short-term investments of $77,945,753. Fixed assets were reported at $13,516,389, while the business reported goodwill and operating lease right-of-use assets of $10,513,371 and $14,002,860, respectively. The company reported total assets and total stockholders’ equity of $151,533,430 and $36,118,732, respectively.

Stock Recommendation:The stock of INO closed at $14.09 with a market capitalization of ~$1.43 billion. The stock made a 52-week low and high of $10.68 and $16.00 and is currently trading at the upper band of its 52-week trading range.  The stock has generated excellent returns of ~490.77% and ~561.50% in the last three months and six months, respectively. In the last one week, the stock has delivered a positive return of 229.20%.With its novel SynCon^® immunotherapy design, the business has shown the ability to help break the immune system’s tolerance of cancerous cells. With the SynCon^® product design approach, the company intended to facilitate cross-strain protection against known and new unmatched strains of pathogens, such as influenza. Recently, the business received orders from WHO for the manufacturing of medicines used for COVID-19.The company’s corporate strategy is to develop, protect and utilize its differentiated immunotherapy platform. Going forward, the company seeks to progress and validate an array of HPV related diseases, as well as cancer and infectious disease immunotherapy and vaccine products. Considering the aforesaid facts, current trading levels and business prospects, we have a wait and watch stance on the stock at the closing price of $14.09, up 43.78% as on 6^th March 2020.

 
INO Daily Technical Chart (Source: Thomson Reuters)

Disclaimer

PLEASE BE ADVISED THAT YOUR CONTINUED USE OF THIS SITE OR THE INFORMATION PROVIDED HEREIN SHALL INDICATE YOUR CONSENT AND AGREEMENT TO THESE TERMS.
References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.
This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332.
The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine is not responsible for material posted on this website and does not guarantee the content, accuracy, or use of the content in this site. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated.
Kalkine do not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not in any way endorse or recommend individuals, products or services that may be discussed on this site. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional licensed financial planner and adviser.